A Phase I Study of Prime-Boost HIV Vaccine Combinations Using Modified Vaccinia Ankara and Adenovirus Type 26 Vectors with Mosaic and Natural Sequence Inserts in Healthy, HIV-Uninfected Adults

Trial Profile

A Phase I Study of Prime-Boost HIV Vaccine Combinations Using Modified Vaccinia Ankara and Adenovirus Type 26 Vectors with Mosaic and Natural Sequence Inserts in Healthy, HIV-Uninfected Adults

Discontinued
Phase of Trial: Phase I

Latest Information Update: 14 Sep 2016

At a glance

  • Drugs HIV vaccine (Primary)
  • Indications HIV infections
  • Focus Adverse reactions; Pharmacodynamics; Pharmacogenomic
  • Sponsors Janssen
  • Most Recent Events

    • 21 Jul 2016 Status changed from suspended to discontinued.
    • 11 Dec 2013 Status changed from not yet recruiting to suspended as reported by Pan-African Clinical Trials Registry.
    • 10 Jun 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top